HomeCompareCLVLF vs ORCC

CLVLF vs ORCC: Dividend Comparison 2026

CLVLF yields 0.39% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLF wins by $329.0K in total portfolio value· pulled ahead in Year 4
10 years
CLVLF
CLVLF
● Live price
0.39%
Share price
$8.45
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.4K
Annual income
$233,845.04
Full CLVLF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CLVLF vs ORCC

📍 CLVLF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLF
Annual income on $10K today (after 15% tax)
$32.77/yr
After 10yr DRIP, annual income (after tax)
$198,768.28/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CLVLF beats the other by $198,767.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLF + ORCC for your $10,000?

CLVLF: 50%ORCC: 50%
100% ORCC50/50100% CLVLF
Portfolio after 10yr
$185.9K
Annual income
$116,923.04/yr
Blended yield
62.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CLVLF
No analyst data
Altman Z
21.3
Piotroski
5/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLF buys
0
ORCC buys
0
No recent congressional trades found for CLVLF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLFORCC
Forward yield0.39%9.79%
Annual dividend / share$0.03$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$350.4K$21.4K
Annual income after 10y$233,845.04$1.04
Total dividends collected$320.5K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CLVLF vs ORCC ($10,000, DRIP)

YearCLVLF PortfolioCLVLF Income/yrORCC PortfolioORCC Income/yrGap
1$10,777$77.10$11,190$489.61$413.00ORCC
2$11,687$155.31$12,229$256.01$542.00ORCC
3$12,820$314.80$13,216$130.74$396.00ORCC
4← crossover$14,363$645.46$14,207$66.02+$156.00CLVLF
5$16,720$1,351.66$15,234$33.17+$1.5KCLVLF
6$20,831$2,941.08$16,317$16.62+$4.5KCLVLF
7$29,138$6,849.18$17,468$8.32+$11.7KCLVLF
8$49,086$17,907.69$18,695$4.16+$30.4KCLVLF
9$108,908$56,386.61$20,006$2.08+$88.9KCLVLF
10$350,377$233,845.04$21,407$1.04+$329.0KCLVLF

CLVLF vs ORCC: Complete Analysis 2026

CLVLFStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CLVLF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLF vs SCHDCLVLF vs JEPICLVLF vs OCLVLF vs KOCLVLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.